FDA reverses course, will review Moderna’s mRNA flu vaccine candidate

The Food and Drug Administration (FDA) has backtracked its archetypal determination past week of refusing to reappraisal Moderna’s mRNA flu vaccine campaigner aft holding a high-priority gathering with the company. Last week, the FDA said it refused to record Moderna’s exertion implicit regulatory issues. The institution maintained that the refusal had thing to bash with…